Louise K Francois Watkins1,2,3, Lesley McGee2, Stephanie J Schrag2, Bernard Beall2, Jennifer Hudson Jain2, Tracy Pondo2, Monica M Farley4, Lee H Harrison5, Shelley M Zansky6, Joan Baumbach7, Ruth Lynfield8, Paula Snippes Vagnone8, Lisa A Miller9,10, William Schaffner11, Ann R Thomas12, James P Watt13, Susan Petit14, Gayle E Langley2,15. 1. Epidemic Intelligence Service Program, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 5. Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland. 6. New York State Department of Health, Albany. 7. New Mexico Department of Health, Santa Fe. 8. Minnesota Department of Health, St Paul. 9. Colorado School of Public Health, University of Colorado Denver, Aurora. 10. Colorado Department of Public Health and Environment, Denver. 11. Vanderbilt University Medical Center, Nashville, Tennessee. 12. Oregon Public Health Division, Portland. 13. California Department of Public Health, Richmond. 14. Connecticut Department of Public Health, Hartford. 15. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
Importance: Group B Streptococcus (GBS) is an important cause of invasive bacterial disease. Previous studies have shown a substantial and increasing burden of GBS infections among nonpregnant adults, particularly older adults and those with underlying medical conditions. Objective: To update trends of invasive GBS disease among US adults using population-based surveillance data. Design, Setting, and Participants: In this population-based surveillance study, a case was defined as isolation of GBS from a sterile site between January 1, 2008, and December 31, 2016. Demographic and clinical data were abstracted from medical records. Rates were calculated using US Census data. Antimicrobial susceptibility testing and serotyping were performed on a subset of isolates. Case patients were residents of 1 of 10 catchment areas of the Active Bacterial Core surveillance (ABCs) network, representing approximately 11.5% of the US adult population. Patients were included in the study if they were nonpregnant, were 18 years or older, were residents of an ABCs catchment site, and had a positive GBS culture from a normally sterile body site. Main Outcomes and Measures: Trends in GBS cases overall and by demographic characteristics (sex, age, and race), underlying clinical conditions of patients, and isolate characteristics are described. Results: The ABCs network detected 21 250 patients with invasive GBS among nonpregnant adults from 2008 through 2016. The GBS incidence in this population increased from 8.1 cases per 100 000 population in 2008 to 10.9 in 2016 (P = .002 for trend). There were 3146 cases reported in 2016 (59% male; median age, 64 years; age range, 18-103 years). The GBS incidence was higher among men than women and among blacks than whites and increased with age. Projected to the US population, an estimated 27 729 cases of invasive disease and 1541 deaths occurred in the United States in 2016. Ninety-five percent of cases in 2016 occurred in someone with at least 1 underlying condition, most commonly obesity (53.9%) and diabetes (53.4%). Resistance to clindamycin increased from 37.0% of isolates in 2011 to 43.2% in 2016 (P = .02). Serotypes Ia, Ib, II, III, and V accounted for 86.4% of isolates in 2016; serotype IV increased from 4.7% in 2008 to 11.3% in 2016 (P < .001 for trend). Conclusions and Relevance: The public health burden of invasive GBS disease among nonpregnant adults is substantial and continues to increase. Chronic diseases, such as obesity and diabetes, may contribute.
Importance: Group B Streptococcus (GBS) is an important cause of invasive bacterial disease. Previous studies have shown a substantial and increasing burden of GBS infections among nonpregnant adults, particularly older adults and those with underlying medical conditions. Objective: To update trends of invasive GBS disease among US adults using population-based surveillance data. Design, Setting, and Participants: In this population-based surveillance study, a case was defined as isolation of GBS from a sterile site between January 1, 2008, and December 31, 2016. Demographic and clinical data were abstracted from medical records. Rates were calculated using US Census data. Antimicrobial susceptibility testing and serotyping were performed on a subset of isolates. Case patients were residents of 1 of 10 catchment areas of the Active Bacterial Core surveillance (ABCs) network, representing approximately 11.5% of the US adult population. Patients were included in the study if they were nonpregnant, were 18 years or older, were residents of an ABCs catchment site, and had a positive GBS culture from a normally sterile body site. Main Outcomes and Measures: Trends in GBS cases overall and by demographic characteristics (sex, age, and race), underlying clinical conditions of patients, and isolate characteristics are described. Results: The ABCs network detected 21 250 patients with invasive GBS among nonpregnant adults from 2008 through 2016. The GBS incidence in this population increased from 8.1 cases per 100 000 population in 2008 to 10.9 in 2016 (P = .002 for trend). There were 3146 cases reported in 2016 (59% male; median age, 64 years; age range, 18-103 years). The GBS incidence was higher among men than women and among blacks than whites and increased with age. Projected to the US population, an estimated 27 729 cases of invasive disease and 1541 deaths occurred in the United States in 2016. Ninety-five percent of cases in 2016 occurred in someone with at least 1 underlying condition, most commonly obesity (53.9%) and diabetes (53.4%). Resistance to clindamycin increased from 37.0% of isolates in 2011 to 43.2% in 2016 (P = .02). Serotypes Ia, Ib, II, III, and V accounted for 86.4% of isolates in 2016; serotype IV increased from 4.7% in 2008 to 11.3% in 2016 (P < .001 for trend). Conclusions and Relevance: The public health burden of invasive GBS disease among nonpregnant adults is substantial and continues to increase. Chronic diseases, such as obesity and diabetes, may contribute.
Authors: Luchang Zhu; Prasanti Yerramilli; Layne Pruitt; Matthew Ojeda Saavedra; Concepcion C Cantu; Randall J Olsen; Stephen B Beres; Andrew S Waller; James M Musser Journal: Infect Immun Date: 2020-09-18 Impact factor: 3.441
Authors: Cassandra R Duffy; Yongmei Huang; Maria Andrikopoulou; Conrad N Stern-Ascher; Jason D Wright; Mary E D'Alton; Alexander M Friedman Journal: J Matern Fetal Neonatal Med Date: 2020-03-11
Authors: Miwako Kobayashi; Lesley McGee; Sopio Chochua; Mirasol Apostol; Nisha B Alden; Monica M Farley; Lee H Harrison; Ruth Lynfield; Paula Snippes Vagnone; Chad Smelser; Alison Muse; Ann R Thomas; Li Deng; Benjamin J Metcalf; Bernard W Beall; Stephanie J Schrag Journal: Open Forum Infect Dis Date: 2020-12-21 Impact factor: 3.835
Authors: Elysia A Masters; Stephanie P Hao; H Mark Kenney; Yugo Morita; Chad A Galloway; Karen L de Mesy Bentley; Benjamin F Ricciardi; Brendan F Boyce; Edward M Schwarz; Irvin Oh Journal: J Orthop Res Date: 2020-12-29 Impact factor: 3.494
Authors: Xin Xu; Alexander L Lewis Marffy; Andrew Keightley; Alex J McCarthy; Brian V Geisbrecht Journal: J Immunol Date: 2022-02-02 Impact factor: 5.422
Authors: Lesley McGee; Sopio Chochua; Zhongya Li; Saundra Mathis; Joy Rivers; Benjamin Metcalf; Alison Ryan; Nisha Alden; Monica M Farley; Lee H Harrison; Paula Snippes Vagnone; Ruth Lynfield; Chad Smelser; Alison Muse; Ann R Thomas; Stephanie Schrag; Bernard W Beall Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079
Authors: Miriam A Guevara; Jacky Lu; Rebecca E Moore; Schuyler A Chambers; Alison J Eastman; Jamisha D Francis; Kristen N Noble; Ryan S Doster; Kevin G Osteen; Steven M Damo; Shannon D Manning; David M Aronoff; Natasha B Halasa; Steven D Townsend; Jennifer A Gaddy Journal: ACS Infect Dis Date: 2020-11-10 Impact factor: 5.084